BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Quintessence Biosciences, Inc. Cancer Drug, QBI-139, Clears FDA Review to Start Phase I Human Trial


12/5/2008 2:30:43 PM

MADISON, WISCONSIN— December 5, 2008 – Quintessence Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the first of the Company’s EVade™ Ribonuclease drug candidates, called QBI-139. The Company will begin a Phase I trial of QBI-139 in patients with solid tumors in the coming months.

Unlike conventional chemotherapies, the EVade™ Ribonuclease technology provides an opportunity to attack RNA in cancer cells, an exciting new drug target, with QBI-139, which is nearly identical to a human protein, pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown significant tumor growth inhibition against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors.

“Clearance of the IND application by the FDA represents the first major clinical development milestone for QBI-139,” said Quintessence Biosciences President Laura Strong. “We are optimistic that QBI-139 will provide a new means to help patients with cancer. There is a clear need for drugs that attack cancer in new ways and ribonuclease therapies are positioned to accomplish that goal.”

About Quintessence Biosciences, Inc.

Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is anticipated to enter a Phase 1 clinical trial in late 2008. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES